Vermont launches Rx drug price web site
A web site intended to allow residents of the state of Vermont, USA, to compare prescription drug prices is a "waste of time," according to the northeastern state's Chairman of the Board of Pharmacy, Earl Pease, the Boston Globe reports.
The initiative, promoted by Vermont's Attorney General, William Sorrell (Democrat), is designed to help local residents who are faced with price variations of 30% or more in the same area.
Mr Pease argued that, with fewer than one in 20 customers paying the cash price, a comparison of prices reported by pharmacists will not take into account co-payments for insured residents or special rates that apply to private and public insurers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze